Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Merger agrmnt [a]
Quarterly results
CC transcript
Inv. presentation
Director departure
Appointed director
AMICUS THERAPEUTICS, INC. (FOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
10/04/2023 4 Crowley John F (Executive Chairman) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 4,444 shares @ $11.079, valued at $49.2k
Sold 1,600 shares @ $11.7075, valued at $18.7k
10/04/2023 4 Campbell Bradley L (President & CEO) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 11,200 shares @ $11.2027, valued at $125.5k
Sold 500 shares @ $12.038, valued at $6k
Exercised 11,700 options to buy @ $2.94, valued at $34.4k
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
09/27/2023 8-K Quarterly results
08/23/2023 4 Harford Simon N.R. (CFO) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Granted 106,973 shares @ $0
Granted 189,043 options to buy @ $12.62, valued at $2.4M
08/23/2023 3 Harford Simon N.R. (CFO) has filed a Form 3 on AMICUS THERAPEUTICS, INC.
08/21/2023 4 Prout Samantha (Chief Accounting Officer) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 7,432 shares @ $12.77, valued at $94.9k
08/21/2023 4 Castelli Jeff (Chief Development Officer) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Paid exercise price by delivering 14,560 shares @ $12.77, valued at $185.9k
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer"
08/16/2023 4 Crowley John F (Executive Chairman) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 6,044 shares @ $13.0268, valued at $78.7k
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom"
08/11/2023 4 Prout Samantha (Chief Accounting Officer) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 36,909 shares @ $14.0056, valued at $516.9k
Exercised 2,376 options to buy @ $10.04, valued at $23.9k
Exercised 5,040 options to buy @ $9.55, valued at $48.1k
Exercised 10,592 options to buy @ $10.03, valued at $106.2k
Exercised 18,901 options to buy @ $12.11, valued at $228.9k
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates",
"2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate..."
08/03/2023 4 Crowley John F (Executive Chairman) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 6,044 shares @ $13.3548, valued at $80.7k
08/03/2023 4 Campbell Bradley L (President & CEO) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 20,000 shares @ $13.3937, valued at $267.9k
Exercised 11,700 options to buy @ $2.94, valued at $34.4k
08/01/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/14/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/12/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 4 Crowley John F (Executive Chairman) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 6,044 shares @ $12.3107, valued at $74.4k
07/06/2023 4 Campbell Bradley L (President & CEO) has filed a Form 4 on AMICUS THERAPEUTICS, INC.
Txns: Sold 11,700 shares @ $12.3091, valued at $144k
Exercised 11,700 options to buy @ $2.94, valued at $34.4k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy